Aims: This study evaluates the agreement between echocardiographic and cardiac magnetic resonace imaging (CMR) data, and the impact a discrepancy between the two may have on the clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
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Introduction:
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be an inherited disease with autosomal dominant inheritance and variable penetrance and phenotype expression [1] [2] [3] . It is characterized by a fibrous and fatty replacement of primarily right ventricular myocardium, and an increased risk of ventricular arrhythmias and sudden cardiac death. The initial presentation varies, but a significant minority of patients present with sudden cardiac arrest as the first symptom, and ARVC may account for up to 25% of exercise related SCD in young individuals 4 . An early correct diagnosis is important, considering the prognostic implications of the disease.
Diagnostic criteria have previously been based on the 1994 task force criteria 5 , but in recognition of new improved imaging techniques and genetic tests, updated diagnostic task force criteria and genetic guidelines have more recently been published 1, 3 . As in the previous version, regional right ventricular (RV) wall abnormalities (aneurysm, dyskinesia or akinesia)
are a prerequisite in imaging-criteria, and the level of RV dilatation determines whether or not a minor or major ARVC criterion is met. A problem with the task force criteria may be that the sensitivity of echocardiography is low for detection of subtle regional RV wall abnormalities. Cardiac magnetic resonance imaging (CMR) is less available than echocardiography, but in centres with the appropriate CMR scanner and experience, the evaluation of RV regional wall abnormalities is presumably more robust due to better quality images (as compared to echocardiography).
The present study aims to explore the diagnostic performance of echocardiography-based imaging criteria for ARVC diagnosis, and compare these data to CMR-based criteria in a cohort based on the Nordic ARVC Registry. The patients in the Nordic ARVC registry have been handled according to standard clinical practice in their respective countries, (i.e. not 5 using any core-lab analyses), thus making the results representative of the "real-world" setting.
Methods:
The Nordic ARVC registry (www.arvc.dk) includes patients with diagnosed ARVC and their first-degree relatives, enrolled from eight centres in Denmark, Norway and Sweden [6] [7] [8] . The study was cross-sectional by design and was based on the patients who were followed in the participating centres and had been entered into the Registry before May 2013, and fulfilled definite ARVC diagnostic criteria according to the Task Force 2010. The study was approved by the regional ethics committee and all individuals signed a written informed consent prior to enrolment in all countries except in Denmark, where this type of observational registry by law does not involve approval by the ethics committee. The study complies with the Declaration of Helsinki.
In the registry, baseline clinical data (age, gender, previous cardiovascular disease, diabetes)
is collected, in addition to ARVC-relevant data for diagnostic criteria as proposed in the guidelines from 1994 and the updated task force criteria from 2010 3, 5 . This includes ARVCrelated symptoms, imaging data from echocardiography, CMR and RV angiography, histology data from cardiac biopsies, electrocardiographic data including depolarisation and repolarisation pathology, ventricular arrhythmia data and family history.
For the purpose of this analysis, all patients included in the Registry with a definite ARVC diagnosis according to 2010 criteria were screened for availability of both CMR and echocardiography. The patients were divided into two groups according to CMR-positive or - 
Results:

Patient population
A total of 179 patients with definite ARVC according to 2010 task force criteria were screened for inclusion, and 102 patients with both echocardiography and CMR data were included in the study (Figure 1 ). On average, the patients had 2.5 major criteria (range 1-5) and 1.0 minor criteria (range 0-3). In 30% of the cases the total score from the other five diagnostic criteria (excluding imaging) would not have been sufficient to reach the definite ARVC diagnosis threshold (i.e. the total ARVC score according to 2010 task force criteria being 1-2 major criteria in combination with 0-2 minor criteria, or 4 minor criteria). The 7 remaining 70% of patients would have been diagnosed as positive regardless of imaging data.
Clinical data is shown in Table 1 .
Imaging data
Imaging data is presented in table 2 and table 3 . The mean time difference between echocardiography and CMR investigation was 5.2 months (IQ range 3.1months), the echocardiography preceded the CMR in 77 of the cases. For 26 patients the timespan was more than a year, and therefore further test analyses were made without these patients, producing results similar to the tests on the whole group (data not shown). On the basis of this, these patients were also included in the final material.
Men were more likely than women to have CMR-positive imaging (79% positive versus 57% females positive, p=0.02). Individuals with CMR positive findings were more likely to have ventricular arrhythmias (77% vs. 57%, p=0.047), but in contrast those with positive findings on echocardiography did not have more arrhythmias (70% vs. 73%, p=0.73). Other baseline ARVC-related clinical data did not differ between CMR groups, except for the expected finding that CMR positive patients were more likely to be "probands" than relatives (88% vs.
57%, p=0.001) and less likely to have a family history of ARVC. Analyzing baseline data by positive/negative echocardiography criteria revealed a trend for echocardiography-positive patients to be probands (86% vs. 71%, p=0.09), but showed no association to arrhythmias (p=0.9). 43% of the "non-probands" had positive findings on CMR, as compared to 31% who had positive findings on echocardiography.
Notably, in 10 CMR-negative patients there were positive echocardiographic criteria (5 major, 4 minor and 1 with regional abnormalities but no volume measurements available).
LVEF and body surface area did not differ between CMR positive and negative patients, but 8 all measures of RV volume were larger in CMR positives (see tables 2 and 3). In identifying patients with regional RV dysfunction and dilatation, the diagnostic performance of echocardiography compared to CMR was poor (Table 4a) . Furthermore, RVOT dilatation on echocardiography showed poor correlation with overall RV dilatation on CMR (p=0.8).
In order to investigate if the sensitivity for echocardiography could be improved (with acceptable specificity) by omitting the requirement for regional wall abnormalities, a similar analysis was done, using Task Force criterion for RV volume measurements only (i.e. the prerequisite for regional wall motion pathology was omitted). This simplification increased the sensitivity to 78% whereas the specificity decreased to only 20% (Table 4b ).
Echocardiography was more sensitive but less specific in probands compared with family members to probands, (Table 5a and 5b). Patients with regional RV wall abnormalities on CMR were more likely to have an arrhythmia fulfilling ARVC major or minor criteria (77% vs. 57%, p=0.047). In contrast, echocardiographic regional RV wall abnormalities did not discriminate between patients with and without arrhythmia criteria (70% vs. 73%, p=0.73).
Discussion
Our study shows that agreement between echocardiography and CMR for evaluation of the 2010 ARVC criteria is low in patients fulfilling definite ARVC diagnosis. Even though echocardiography evaluations of right ventricular volumes point in the same direction as CMR based evaluations (as shown in table 2), the discrepancy in fulfilment of diagnostic criteria may have clinical implications since imaging data becomes a pivotal diagnostic criterion in a significant amount of the cases. It seems that in particular the detection of regional RV structural abnormalities was difficult, but echocardiography based measures of RVOT dilatation also showed a poor correlation with CMR based measures of RV dilatation.
This indicates that ARVC may present with segmental RV dilatation, excluding the outflow 9 tract, and thereby not fulfilling echocardiography based task force criteria. The present cohort is larger than previously published ARVC cohorts evaluated using CMR, and is based on all known ARVC cases in the uptake areas of the participating sites in Scandinavia. Compared to the cohort on which the current 2010 task force recommendations are based, the present cohort included more cases, and in particular more cases with both CMR and echocardiography evaluation 3 .
The data in this study was collected retrospectively, and there was a time-lapse between the CMR and echocardiography investigations in some patients. Presuming that ARVC in some patients is a progressive disease, this time-difference may have had an impact on the difference in positive findings -favouring CMR data, which was collected 5 months later on average.
Assessment of right ventricular size and volume
The 2010 Task Force criteria are based on a cohort of data from 108 probands with newly diagnosed ARVC, including 44 individuals with a CMR performed. Data was compared to different cohorts with appropriate normal subjects, and cut-off values for imaging were determined as the value that yielded 95% specificity (major criterion), and sensitivity ranged from 79%-89% (major) and 68%-78% (minor) 3 .
Measurements of RV volume measurements differ between CMR and echocardiography, and
it is important to recognize that these data are based on different methods. The shape of the RV is complex and makes it inherently difficult to assess both the size and systolic function in a reproducible fashion, especially when using 2D images 9 . Even though quantitative measurements have been shown to significantly increase sensitivity and specificity in echocardiographic evaluation of the RV, angulation of the probe is still crucial. Depending on 10 which angulation is used, the size of the RV varies considerably, which is reflected by a significant variability of results even in experienced hands. The method is particularly vulnerable, since RV size is calculated quantitatively by one 2D projection only (the standard 4 chamber view). The new 3D based technique is promising and has shown lower interindividual variability than 2D measurements 10 , but many patients do not offer acoustic windows that allow for the entire RV to be evaluated by 3D. In addition, the current ARVC guidelines do not include 3D volume measurements by echocardiography, thus 3D based echocardiography measurements were not performed in our cohort.
Assessment of right ventricular regional wall motion abnormalities
We used CMR based task force 2010 criteria as "gold-standard" for comparison with the echocardiography results. Interpretation of CMR may be more reliable due to more precise definition of the endocardial and myocardial layers and freedom of projection of the images in any preferred direction, once a proper collection of raw data has been made. A theoretical risk of applying CMR data as "gold-standard" is that it may lead to over-diagnosing of small regional abnormalities in the RV, which may in fact not be related to the disease (and which would not have caught any attention in an echocardiographic examination). Previous studies have pointed to some inter-individual variation in interpretation of CMR in patients with suspected ARVC, and optimally one would need pathology specimen for comparison 11, 12 .
However, in lack of this, we believe that CMR in experienced hands (such as the tertiary referral centres of this study) should be regarded as gold standard when it comes to evaluation of early structural changes in ARVC.
Segmental evaluation of the right ventricle is challenging due to the complex shape of the chamber and the position of the RVOT immediately under the sternum, narrowing down the acoustic window for some parts of the myocardium. In recognition of this, newer techniques 11 such as tissue-doppler and speckle tracking strain analysis have been used in order to improve the sensitivity for diagnosing RV structural disease [13] [14] [15] [16] . However, some of these studies are hampered by the low feasibility of speckle tracking evaluation of the free wall (58% in the study by Aneq et al. 13 ) and the time-consuming and operator dependent results generated from tissue-doppler imaging. The most promising results were reported by Teske et al. on a cohort of mutation-positive but asymptomatic individuals, compared with a control group 15 . They could show a high feasibility (>90%), and diagnostic sensitivity and specificity of echocardiography could be improved to 71% sensitivity and 81% (speckle tracking) -100%
(TDI) specificity. Vermont et al. studied 69 patients who fulfilled major imaging criteria according to the 1994 guidelines, but only 38% of these patients met minor or major imaging criteria of 2010 -the main reason for this, according to the authors, being a lack of the distinct regional RV wall pathology required in the 2010 criteria 17 .
Diagnosing ARVC
The importance of a high sensitivity for diagnosing early disease is emphasized by the findings that sudden cardiac death occurs also in individuals with no or subtle evidence of structural heart disease 18, 19 . It is also important to distinguish between individuals with advanced disease, where gross RV pathology is present, and the diagnosis is easy by any given imaging modality, and individuals with pre-symptomatic disease where no structural changes can be seen. On the other hand, in subjects with non-specific symptoms and / or subtle abnormalities, there is of course also a risk of over-diagnosing disease, especially by inexperienced interpreters. This was highlighted by the two studies of Sen-Chowdhry and Bomma, and the importance of looking at all different aspects of the task force criteria was emphasized 20, 21 . This conclusion is firmly supported by our results, and we believe it is important that all diagnostic imaging possibilities are used in order to maximize sensitivity 12
and specificity for correctly diagnosing ARVC. CMR more often has the potential to "catch" family members with early subclinical disease, compared to echocardiography, but in some cases echocardiography is positive when CMR is negative. In some of the cases, the CMR preceded the echocardiography in time; this may explain why some structural alterations were detected by echocardiography and not by CMR. In other instances it may be that the changes were overlooked in the CMR setting, or that normal trabeculation has been interpreted as regional wall abnormality if the image quality was suboptimal. Therefore, in particular for cases where the diagnosis depends on the presence or absence of imaging criteria, both CMR and echocardiography should be performed. Unless excellent image quality is provided by echocardiography, serial evaluation by CMR should be considered if the findings are ambiguous or non-diagnostic. This is also supported by the finding that regional RV pathology on CMR was associated with ventricular arrhythmias -as opposed to regional RV pathology on echocardiography, which was not associated with arrhythmias.
There is a difference in the diagnostic performance of echocardiography in probands as compared to family members, detected by screening programmes (as presented in tables 5a
and 5b), which probably reflects the fact that probands with mostly symptomatic disease are more likely to have structural manifestations of the disease as well. When the structural abnormalites are more pronounced they are also more likely to be detected by echocardiography, even if the image quality is not optimal. This makes it even more important to include CMR in the screening of asymptomatic relatives at risk of disease, where the sensitivity of echocardiography is clearly unacceptably low. A revision of the current guidelines may be considered, and one option could be to add CMR as a compulsory modality for evaluation of regional abnormalities, unless already visualised positively by echocardiography. New cut-off limits might need to be considered, and should be based on data from multiple large cohorts. 13
Limitations:
The major limitation is the retrospective data collection, resulting in a time difference between when echocardiography and CMR investigations were performed, and in some instances the interpreting physician may have been aware of the previous results from other imaging modalities, possibly introducing a bias. Nevertheless, the population is large, and the majority of patients had only a small timespan between the two investigations, thus making the results reliable even with the limitation of retrospective data collection. The cohort did not include any matched controls, and the diagnostic performance of different echocardiography cut-off values could therefore not be evaluated in a "general population". The investigations
were not performed by a core lab, but at eight different tertiary referral University Hospitals.
This will likely have resulted in a greater variability in the evaluations, but conversely the results are more likely to reflect the "real-world" diagnostic performance of echocardiography and CMR, since imaging results for most patients with suspected ARVC would not routinely be subject to secondary evaluation from a certified core lab. The present study therefore does not intend to suggest specific cutoff-values for the diagnostic criteria in ARVC, but rather to offer an insight into the ambiguity and level of difficulty for image-interpretation in patients with suspected or confirmed ARVC.
Conclusion
Evaluation of regional structural changes of the right ventricle using echocardiography is difficult, and the sensitivity for detection of ARVC criteria is lower than for CMR-based images. A significant number of patients with imaging-positive ARVC by CMR showed normal echocardiographic study at baseline, and the correct diagnosis could have been missed. These findings indicate that both echocardiography and CMR should be performed 14 when there is a clinical suspicion of ARVC, and the difference in diagnostic performance should be reflected in the guidelines.
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